Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 +0.92%88 Cyclically Adjusted PB Ratio is 10.65 as of Aug. 10, 2026, which is 42% below its 10-year median of 18.41. GuruFocus rates SHSE:688656 with a GF Score™ of 88/100 and a GF Value™ of ¥81.10 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 520 Medical Devices & Instruments companies, HOB Biotech Group ranks worse than 93.08% on this metric.
The historical rank and industry rank for HOB Biotech Group's Cyclically Adjusted PB Ratio or its related term are showing as below:
SHSE:688656'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 10.55 Med: 18.41 Max: 20.73
Current: 10.55
During the past 10 years, HOB Biotech Group's highest Cyclically Adjusted PB Ratio was 20.73. The lowest was 10.55. And the median was 18.41.
SHSE:688656's Cyclically Adjusted PB Ratio is ranked worse than 93.08% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs SHSE:688656: 10.55
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
HOB Biotech Group's adjusted book value per share data of for the fiscal year that ended in Dec25 was ¥12.918. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ¥8.52 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
HOB Biotech Group (SHSE:688656) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
HOB Biotech Group Cyclically Adjusted PB Ratio Related Terms
HOB Biotech Group Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group Cyclically Adjusted PB Ratio Chart
SHSE:688656 vs ABT, SYK, MDT: Cyclically Adjusted PB Ratio Comparison
For the Medical Devices subindustry, HOB Biotech Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Cyclically Adjusted PB Ratio falls into.
HOB Biotech Group Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
HOB Biotech Group's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 10.65 mean?
HOB Biotech Group (SHSE:688656) has a Cyclically Adjusted PB Ratio of 10.65 as of Aug. 10, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on HOB Biotech Group and its competitors. This is 42% below median its historical median of 18.41. Over the past decade, HOB Biotech Group's Cyclically Adjusted PB Ratio has ranged from 10.55 to 20.73. According to the industry distribution chart, HOB Biotech Group ranks #484 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 93.1%.
Is HOB Biotech Group's Cyclically Adjusted PB Ratio too high?
HOB Biotech Group's current Cyclically Adjusted PB Ratio of 10.65 is 42% below median its 10-year median of 18.41. Over the past 10 years, this metric has ranged from a low of 10.55 to a high of 20.73. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.87. HOB Biotech Group's value of 10.65 is 471% above this industry median. Based on the distribution chart, HOB Biotech Group ranks #484 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HOB Biotech Group has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Cyclically Adjusted PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #484 out of 520 companies for Cyclically Adjusted PB Ratio. This places HOB Biotech Group in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.87. HOB Biotech Group's value of 10.65 is 471% above this benchmark. Historically, HOB Biotech Group's own Cyclically Adjusted PB Ratio has ranged from 10.55 to 20.73 over the past decade. While the company's 10-year median is 18.41 vs. the industry median of 1.87, HOB Biotech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.87, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Cyclically Adjusted PB Ratio of 10.65 is 471% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Cyclically Adjusted PB Ratio is 10.65, which is 42% below median its own 10-year median of 18.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥81.10, compared to a current price of ¥90.70 — trading 11.8% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 10.65, which is 42% below median its 10-year median of 18.41 and 471% above the Medical Devices & Instruments industry median of 1.87. HOB Biotech Group's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Cyclically Adjusted PB Ratio is 10.65 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be overvalued.
The current stock price of ¥90.70 is trading 11.8% above its estimated GF Value™ of ¥81.10.
GuruFocus considers HOB Biotech Group to be Modestly Overvalued.
Key valuation signals for SHSE:688656:
Cyclically Adjusted PB Ratio: 10.65 (42% below median its 10-year median of 18.41)
GF Value™: ¥81.10 vs. price of ¥90.70 (11.8% above fair value)
Industry Position: 471% above the Medical Devices & Instruments median (#484 of 520)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
88GF Score
Get the complete analysis for SHSE:688656
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
